This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants


Cornelli, Umberto


Neuro-Degenerative Diseases, Volume: 7, No.: 1-3, Pages.: 193-202

Year of Publication



A formula (formula F) was prepared to counteract oxidative stress (OS) in the brain. The formula contained the most common antioxidants and was intended to: (a) protect proteins, lipids, DNA and proteoglycans from oxidation (carnosine, coenzyme Q(10), vitamin E, vitamin C, beta-carotene, selenium, L-cysteine and ginkgo biloba); (b) reduce homocysteine (HCy) blood levels (vitamins B(6), B(9) and B(12)), and (c) sustain the pentose phosphate cycle in circulating cells (vitamins B(1), B(2) and B(3)). Formula F contained low doses of each antioxidant component and was administered in a two-phase ampoule. A cohort of 52 patients (21 males and 31 females) affected with moderate probable AD (according to NINCDS-ARDA and NINCS-AIREN criteria) already being treated with donepezil (5 mg/day for at least two months) was randomly divided into two groups, and followed for 6 months. A double-blind design was used in which 26 cases were treated once a day with formula F plus donepezil, and the other 26 with placebo plus donepezil. The level of OS was measured on the basis of a d-ROMs test (which measures plasma hydroperoxides), plasma HCy and glutathione, and percentage of sickle erythrocytes. The two patient groups were comparable for all variables (age, sex, concomitant diseases, ApoE epsilon4, MMSE II score, OS, antioxidant reserve and sickle erythrocytes). Forty-eight subjects completed the trial. Significant decreases in OS and HCy were only observed when there was an increase in glutathione (in erythrocytes) and a decrease in sickle erythrocytes in patients treated with formula F. The MMSE II score remained almost the same in the group treated with donepezil and placebo, whereas some significant improvements were found in the group treated with donepezil plus formula F.; Copyright 2010 S. Karger AG, Basel.

Bibtex Citation

@article{Cornelli_2010, doi = {10.1159/000295663}, url = {}, year = 2010, publisher = {S. Karger {AG}}, volume = {7}, number = {1-3}, pages = {193--202}, author = {Umberto Cornelli}, title = {Treatment of Alzheimer's Disease with a Cholinesterase Inhibitor Combined with Antioxidants}, journal = {Neurodegenerative Diseases} }


aged, aged, 80 and over, alzheimer disease, antioxidants, bisphenol aglycidyl methacrylate, blood, cholinesterase inhibitors, cohort studies, double-blind method, drug effects, drug therapy, drug therapy combination, female, homocysteine, humans, indans, male, methods, models biological, oxidative stress, piperidines, polyurethanes, proteoglycans, reactive oxygen species, therapeutic use, time factors, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions